Clinical Digest: A Comprehensive Review of Recent Astrazeneca Clinical Trials
This compilation provides an overview of Astrazeneca‘s recent clinical trial activity, encompassing up to 200 of their latest trials. Alongside these trials are potentially related publications, patents, and grant funding, which may include work from Astrazeneca or other entities exploring similar therapeutic areas. This resource aims to offer researchers, clinicians, investors, and the broader public insights into Astrazeneca’s current research and development pipeline. By presenting clinical trial details alongside related intellectual property and financial backing (regardless of origin), this compilation facilitates a broader understanding of Astrazeneca’s strategic focus and how it potentially compares to direct and indirect competitors in these therapeutic spaces. This information can be valuable for identifying emerging trends in drug development, assessing the commercial potential of specific research programs, and understanding the broader landscape of scientific contributions related to Astrazeneca’s clinical trials. (Last updated on: 2025-05-20)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: A Comprehensive Review of Recent Astrazeneca Clinical Trials
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term observation of safety and efficacy in these participants treated with brazikumab. There are no formal hypotheses to be tested. Safety and efficacy data obtained in this study will be included in regulatory product submissions as appropriate. |
ASTRAZENECA | 2025-05-19 |
| 2 | A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess The Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With A P-gp Inhibitor in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to assess the effect of food on balcinrenone/ dapagliflozin pharmacokinetics in fed and fasted state and pharmacokinetics of balcinrenone when dosed with a P-gp inhibitor in healthy participants. |
ASTRAZENECA | 2025-05-19 |
| 3 | A Phase III Double-blind Randomised Study Assessing The Efficacy and Safety of Capivasertib/+Paclitaxel Vs Placebo+Paclitaxel As First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC) |
PETER SCHMID; | 2025-05-16 |
| 4 | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib). |
NADIA HARBECK; | 2025-05-16 |
| 5 | A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 As Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents |
ASTRAZENECA | 2025-05-16 |
| 6 | Retrospective Real World Evidence Study to Describe Characteristics and Outcomes in Dutch Patients Admitted to The Hospital With A Factor Xa Inhibitor-associated Bleeding Treated With Andexanet Alfa PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational retrospective database study of hospitalized patients treated with andexanet alfa in approximately 10 Dutch hospitals. Currently there is limited information on the patient characteristics and outcomes of patients who are treated with andexanet alfa in The Netherlands and how it is used. This is of interest for treating clinicians because there is a need for a patient profile, also due to the on par position of andexanet alfa with PCC in the Dutch national guideline. Analysis of the data showed that 14 patients of the 218 patients included in the study (6.4%) experienced a thrombotic event (TE) within 30 days after treatment with andexanet alfa. The protocol was amended to allow for an in depth analysis of the 14 TE cases. |
ASTRAZENECA | 2025-05-16 |
| 7 | A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate The Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD. |
ASTRAZENECA | 2025-05-16 |
| 8 | A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate The Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity |
ASTRAZENECA | 2025-05-16 |
| 9 | An Open-label, Randomized, Cross-over, Single Dose Study in Healthy Participants to Assess The Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Quinidine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants. |
ASTRAZENECA | 2025-05-16 |
| 10 | A Phase I, Randomized, Single Blinded, Placebo-controlled Study to Assess The Safety, Tolerability, and Pharmacokinetics of AZD0233 Following Single and Multiple Ascending Dose Administration in Healthy Male and Female Participants 18 to 50 Years of Age PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants. |
ASTRAZENECA | 2025-05-16 |
| 11 | A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate The Effect of Hepatic Impairment on The Pharmacokinetics, Safety, and Tolerability of AZD5004 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function. |
ASTRAZENECA | 2025-05-16 |
| 12 | A Multinational, Observational, Retrospective, Secondary Data Study Describing Management and Treatment in Routine Clinical Practice Among Patients With Chronic Kidney Disease. Local Adaptation for Spain. Part 1 PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: OPTIMISE-CKD is a retrospective, observational study, using secondary data. The incidence of renal disease, including CKD, using eGFR or UACR laboratory measurements and diagnostic codes will be assessed in the study population. The study will also assess the incidence of selected cardiovascular and renal events and the current use of kidney-protective treatments |
ASTRAZENECA | 2025-05-15 |
| 13 | Heart Failure Patients Registry A Prospective Observational Multicenter Registry of Patients With Chronic Heart Failure in The Population of The Russian Federation (PRIORITY-HF) PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multicenter non-interventional observational prospective registry. This non-interventional study (NIS) does not imply any intervention into a routine clinical practice, including choice of treatment modality or special methods of investigation. The study will include only those patients who sign the informed consent form (ICF) after explanation of the study objectives and methods by the study physician. Planned study population consists of 20 000 adult outpatients with HF. All patients with HF who signed an ICF will be included to this study. Planned number of study sites is 150 outpatient centers in about 50 regions (in order to describe characteristics of outpatients with HF in different regions in the most comprehensive way). Expected inclusion period duration – 24 months OR reaching 20 000 patients, if this takes less than 24 months. Planned follow-up period duration for 1 patient is about 52 weeks (12 months), which includes 3 visits (visit 1 – inclusion; visit 2 – approximately 6 months after inclusion; visit 3 – approximately 12 months after inclusion) |
ASTRAZENECA | 2025-05-15 |
| 14 | An Observational Multicenter Cross-sectional Study of Patients With Uncontrolled Severe Asthma in The Population of The Russian Federation PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics). Planned number of study site is 50 outpatient centers with experience of uncontrolled SA treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled SA in different regions in the most comprehensive way). This non-interventional study does not imply any intervention into a routine clinical practice, and does not provide for any diagnostic and therapeutic procedures other than those used in routine practice. |
ASTRAZENECA | 2025-05-15 |
| 15 | A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician’s Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC. |
KIM NGUYEN CHI; | 2025-05-15 |
| 16 | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate The Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria |
ASTRAZENECA | 2025-05-15 |
| 17 | A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for The First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician’s choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer |
ASTRAZENECA | 2025-05-15 |
| 18 | A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed By Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC. |
ASTRAZENECA | 2025-05-15 |
| 19 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck Previously Treated With An Immune Checkpoint Inhibitor PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer. |
ROGER B COHEN; | 2025-05-15 |
| 20 | A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma. |
ASTRAZENECA | 2025-05-15 |
| 21 | A Phase II, Open-label, Multicenter, Master Protocol to Evaluate The Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC). |
ASTRAZENECA | 2025-05-15 |
| 22 | A Phase 2a, Randomised, Single-blind, Placebo-controlled Study to Evaluate The Safety, Tolerability, and Pharmacokinetics and Explore The Pharmacodynamic Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the safety, tolerability, and the way the body absorbs, distributes, and metabolises AZD2389 as compared to placebo in participants with liver fibrosis and compensated cirrhosis. The study will also examine how the drug acts on the body |
ASTRAZENECA | 2025-05-15 |
| 23 | A Phase Ib Open Label Positron Emission Tomography Study to Assess Changes in Intestinal [11C]AZ14132516 Uptake Following Administration of Multiple Doses of AZD7798 to Patients With Crohn’s Disease PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the changes in intestinal uptake of radioligand \[11C\]AZ14132516 following multiple doses of AZD7798 in participants with Crohn’s disease. |
MARIA CREIGNOU; | 2025-05-15 |
| 24 | An Open-label, Phase I Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM. Study details include: • The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2. |
ASTRAZENECA | 2025-05-15 |
| 25 | An Open-label, Fixed Sequence Study in Healthy Participants to Assess The Effect of Multiple Doses of AZD2389 on The Pharmacokinetics of Midazolam, Caffeine, and Bupropion PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the effect of multiple doses of AZD2389 on the pharmacokinetics (PK) of midazolam, caffeine, and bupropion in healthy participants. |
ASTRAZENECA | 2025-05-15 |
| 26 | A Modular Phase I, Open-label Study to Assess The Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase I modular study to assess the effect of oral saruparib on other treatments in patients with advanced solid malignancies. |
ASTRAZENECA | 2025-05-15 |
| 27 | An Open-label, Fixed-sequence, Three-part Study to Assess The Effect of AZD5004 on The Pharmacokinetics of Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and to Assess The Effect of Erythromycin on AZD5004 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the effect of Erythromycin on AZD5004 in healthy adult male and female participants. |
ASTRAZENECA | 2025-05-15 |
| 28 | EXCEED – A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide As Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an intention-to-treat approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a … |
FABIAN HOTI; | 2025-05-14 |
| 29 | Chronic Kidney Disease Registry Platform Study PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical characteristics, diagnostic and treatment patterns, and clinical outcomes of patients with chronic kidney disease (CKD), to describe the current status of the diagnosis and treatment of patients with CKD and the gaps from the diagnostic and treatment guidelines, explore the risk factors for disease progression and clinical outcomes in CKD patients, and construct a risk prediction model for CKD progression and clinical outcomes |
BICHENG LIU; | 2025-05-14 |
| 30 | A Phase III, Randomised, Double-blind Study to Evaluate The Effect of Balcinrenone/Dapagliflozin, Compared With Dapagliflozin, on The Risk of Heart Failure Events and Cardiovascular Death in Patients With Heart Failure and Impaired Kidney Function PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events. |
ASTRAZENECA | 2025-05-14 |
| 31 | Boosting Regional Integration for COPD Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle: A Multicentre , Prospective, Cluster Randomization, Inteventional Clinical Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a cluster randomized interventional study. Intervention is implemented at a hospital level and will change overall daily practice. 36 county level hospitals are r an domized to the intervention group or control group at the ratio of 2:1 . Total subjects is 1368 and a size of 38 per hospital . |
ASTRAZENECA | 2025-05-14 |
| 32 | A Phase III, Double-blind, Randomised Study to Assess The Safety and Efficacy of AZD9291 Versus A Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer |
ASTRAZENECA | 2025-05-14 |
| 33 | Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor receptor 2 (HER2)-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer (BC) receiving T-DXd in line with the applicable summary of product characteristics (SmPC) within routine clinical practice in Germany. In addition, patients will be informed about use of digital healthcare application (DiGA). |
ASTRAZENECA | 2025-05-14 |
| 34 | A Phase IIIb Single Arm, 2 Cohorts Study Assessing The Efficacy and Safety of Capivasertib+ Fulvestrant As Treatment for Locally Advanced(Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With Endocrine Therapy in Chinese Patients PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy. The Primary objective is to assess the efficacy of capi+ful by assessment of TFST (Time to first subsequent treatment) in cohort1. |
ZEFEI JIANG; | 2025-05-14 |
| 35 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for The First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1. |
ASTRAZENECA | 2025-05-14 |
| 36 | A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate The Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), in Patients With Hyperkalemia-HARMONIZE Asia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following 24 or 48 hours of initial ZS therapy (10g TID). |
ASTRAZENECA | 2025-05-14 |
| 37 | The EVOLVE Study: A Prospective, Observational Study to Evaluate Patient-centered Outcomes Over 2 Years of Treatment With Tezepelumab in Real-life Clinical Practice in Greece PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Tezepelumab is a first-in-class human monoclonal antibody for uncontrolled severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), a key epithelial cytokine inducing both Type 2 and non- Type 2 inflammatory pathways. Considering the recent addition of tezepelumab to the severe asthma therapeutic arsenal, there is a need for real-world evidence that can inform treatment-decision making in clinical practice and support regulatory decisions. EVOLVE is a prospective, observational study designed to generate real-world evidence on patient-reported outcomes of treatment with tezepelumab, assessing the effectiveness over a 2-year period in routine care settings in Greece. The study plans to enroll 150 adult patients at an allocation ratio of: i) 70 percent Type 2-high/30 percent Type 2-low, and ii) 80 percent biologic naïve/20 percent switching from a prior biologic. Eligible patients must be newly prescribed tezepelumab according to the approved label. Primary data will be collected at enrollment and 4, 12, 24, 52, 72 and 104 weeks after treatment initiation through visits as per the standard clinical practice in various healthcare settings (20-25 sites) across the country. The primary objective is to describe the patient-reported asthma symptom control using the Asthma Control Questionnaire (ACQ-6) … |
ASTRAZENECA | 2025-05-14 |
| 38 | A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, A Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL). |
ASTRAZENECA | 2025-05-14 |
| 39 | A Phase II, Open Label, Single-arm Study to Assess The Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour A T790M Mutation Within The Epidermal Growth Factor Receptor Gene PF:3 Related Papers Related Patents Related Grants Related Experts Abstract: This is a phase II, open label, single arm study assessing the safety and efficacy of AZD9291 (80 mg, orally, once daily) in Asia Pacific patients with a confirmed diagnosis of … |
ASTRAZENECA | 2025-05-14 |
| 40 | A Multicentre, Randomised, Double-blind, Active-Controlled, 2-arm Parallel-group Treatment, Phase II Study to Evaluate The Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria (ZODIAC) |
ASTRAZENECA | 2025-05-14 |
| 41 | A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine The Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Abstract: This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative global study to determine the efficacy and safety of durvalumab + olaparib combination … |
JONATHAN ROSENBERG; | 2025-05-14 |
| 42 | A Phase I, Randomized, Double-blind, Single-dose, Partial Replicate, 3-way Cross-over Study to Assess The Total Systemic Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered By BGF MDI HFO Compared With BGF MDI HFA in Healthy Adult Participants PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 µg/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants. |
ASTRAZENECA | 2025-05-14 |
| 43 | Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Acalabrutinib received European Medicines Agency approval on November 2020 for for CLL adult patients, either as monotherapy or in combination with obinutuzumab, in previously untreated patients or as monotherapy in patients who have received at least one prior therapy and is reimbursed in Romania since January 2023. In the absence of disease registries or national datasets patient population receiving acalabrutinib in real life setting is not well characterized. The study aims to look into this population outcomes and clinical characteristics having as primary objective time to discontinuation by line of treatment and secondary objectives: reasons for discontinuation, effectiveness of acalabrutinib in real-life practice, baseline clinical and demographic characteristics, treatment patterns and major determinants of treatment discontinuation. The study will retrospectively collect longitudinal data from 250 patients at national level,at pre-defined timepoints for 3 years, from 2 sequential cohorts,1st one enrolled on December 2023 and 2nd one enrolled in December 2024 based on the acalabrutinib start year.. |
ASTRAZENECA | 2025-05-14 |
| 44 | A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I Pharmacokinetic Comparability Study of Tozorakimab Administered Using An Accessorised Prefilled Syringe (APFS) or An Autoinjector (AI) in Healthy Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants. |
ASTRAZENECA | 2025-05-14 |
| 45 | Clinical Observational Study of Remote, Non-invasive, Multidomain Endpoints in Patients Recovering From Acute Decompensated Heart Failure PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the utility of a wearable heart monitoring patch that can be worn on the body to collect various measurements related to heart failure and develop a concept to potentially be used as a new measurement. It is crucial to test out new ways that make it easier to do research for new drugs and increase our chances of knowing how well they will work early on in the development process. Results from this study will be useful in planning future development programs for drugs aimed at treating patients with heart disease. This study will be conducted in a single hospital, it is non-randomised (not chosen by chance), exploratory, study in the United Kingdom (University Hospitals of Leicester NHS Trust). It aims to involve up to 80 men and women recently admitted due to sudden, severe heart failure symptoms. Participants will be part of the study for about two months, with one hospital visit after discharge, as commonly done in heart failure centres. – Visit 1 (Enrolment/Screening) will assess the participant’s eligibility for participating in the study and for collecting baseline data immediately prior to discharge following hospitalisation for acute decompensated heart failure (ADHF). Participants will … |
IAIN SQUIRE; | 2025-05-14 |
| 46 | A Randomized, Open-label Study to Assess The Efficacy and Safety of Olaparib Versus Enzalutamide or Abiraterone Acetate in Chinese Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With A New Hormonal Agent and Have BRCA1/2 Mutations (PROfound-CN) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations. |
FANGJIAN ZHOU; | 2025-05-14 |
| 47 | A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess The Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause. |
TONI K CHOUEIRI; | 2025-05-14 |
| 48 | A Phase I/II, Single-Arm, Open Label Study to Evaluate The Pharmacokinetics, Safety/Tolerability and Efficacy of The Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to \< 7 years with NF1 related symptomatic, inoperable PN. |
ASTRAZENECA | 2025-05-14 |
| 49 | A Phase III Single-Arm Open-Label Study to Evaluate The Safety PK ADA and Anti RSV NAb Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants With CHD, CLD, Immunocompromise, Down Syndrome, or Born Pre-Term in Japan PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months. Study details include * The study duration is approximately 21 months with a 2-month enrollment period. * Study intervention is 2 doses administered 5- 6 months apart. * The study has 5 or 6 site visits and several telephone contacts with a 2 or 4 week interval. |
ASTRAZENECA | 2025-05-14 |
| 50 | A Phase I Randomized, Single-blind, Placebo-controlled, and Sequential Group Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Intravenous Administration, and An Open-label, 2-Period, 2-Sequence, Cross-over Study to Assess The Effects of Intravenous AZD4144 on Rosuvastatin and Furosemide Pharmacokinetics in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144 |
ASTRAZENECA | 2025-05-14 |
| 51 | FASENRA Regulatory Postmarketing Surveillance in Korea PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: As part of a post approval commitment, the MFDS has requested a study to characterize safety in patients who are treated with FASENRA for severe eosinophilic asthma and/or eosinophilic granulomatosis with polyangiitis (EGPA) by physicians in normal clinical practice settings. This study is designed to confirm or assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of FASENRA under conditions of routine daily medical practice in Korea. |
ASTRAZENECA | 2025-05-14 |
| 52 | A Phase I, Open-label Study to Assess The Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies Related Papers Related Patents Related Grants Related Experts Highlight: This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of \[14C\]-Saruparib in patients with advanced solid malignancies. This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable). |
ASTRAZENECA | 2025-05-14 |
| 53 | Implementation of A Lung Cancer Screening Program in A Public Service, Using Low-dose Tomography and Metabolomics Evaluation PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service. |
ERICA N HASIMOTO; | 2025-05-13 |
| 54 | Prospective Non-interventional Study (NIS) to Examine The Effectiveness of Tremelimumab + Durvalumab + Platinum Chemotherapy (TDC) in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective, multicenter, non-interventional study (NIS) in Germany aims to collect real-life data of patients with non-squamous (NSQ) metastatic non-small cell lung cancer (mNSCLC) (incl. large cell neuroendocrine carcinoma (LCNEC) if considered NSCLC-like by the treating physician) for whom 1st line treatment initiation with tremelimumab and durvalumab in combination with a platinum-based chemotherapy (TDC) according to marketing authorization was scheduled. The study aims to describe the effectiveness with respect to mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), Serine/threonine kinase 11 (STK11), Kelch-like ECH-associated protein 1 (KEAP1), and Tumor protein p53 (TP53) as well as expression of Thyroid transcription factor 1 (TTF-1) and Programmed death-ligand 1 (PD-L1) in routine clinical practice. The generated data aims to deepen the understanding of optimal, biomarker-guided treatment strategies for NSQ mNSCLC in distinct subgroups with a high medical need. |
ASTRAZENECA | 2025-05-13 |
| 55 | INTERSTELLAR – Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: INTERSTELLAR study will generate critical prospective real-world evidence on the benefits of adding Anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. The study will use clinical assessments that are relevant for SLE-treating physicians in routine clinical practice, as well as introduce a specific measure for skin manifestations to affirm the potency of anifrolumab in treating SLE-related skin manifestations. The study will use standardized objectives, inclusion/exclusion criteria and outcome measures across all countries participating in this study including GCC (Qatar, KSA), Mexico, CAMCAR (Costa Rica, Panama, Dominican Republic), Colombia, Argentina, Taiwan, and Egypt, and any other countries that may be included in the study, in order to facilitate a comparison and analysis across all countries included in this study. |
ASTRAZENECA | 2025-05-13 |
| 56 | A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2 |
ASTRAZENECA | 2025-05-13 |
| 57 | A Phase IIIB Study to Evaluate The Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with PIK3CA/AKT1/PTEN-altered following recurrence or progression on or after endocrine therapy and CDK4/6 inhibitor. |
ASTRAZENECA | 2025-05-13 |
| 58 | A Phase II, Multicenter, Open-label Study to Evaluate The Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) As Monotherapy or in Combination With Anti-cancer Agents for The Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy. |
ASTRAZENECA | 2025-05-13 |
| 59 | Chronicling The COPD Patient Journey and Change in Impact of A Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF](CHRONICLES COPD) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol \[BGF\] in a real-world setting. |
CHRISTOPHER JAMES LICSKAI; | 2025-05-13 |
| 60 | Specific Use-results Study of IMFINZI Intravenous Infusion 120 Mg,500mg in Patients With Curatively Unresectable Biliary Tract Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To investigate onset of adverse drug reactions in patients with curatively unresectable biliary tract cancer who receive IMFINZI in combination with gemcitabine hydrochloride and cisplatin under actual use in the post-marketing setting. |
ASTRAZENECA | 2025-05-13 |
| 61 | A Non-interventional, Prospective Study With Benralizumab to Investigate Clinical Outcome Based on Standard of Care Medication in Real-life PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany. |
ASTRAZENECA | 2025-05-13 |
| 62 | A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate The Effect of Renal Impairment on The Pharmacokinetics, Safety, and Tolerability of AZD5004 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with severe renal impairment and moderate renal impairment (optional) compared with male and female participants with normal renal function. |
ASTRAZENECA | 2025-05-13 |
| 63 | A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate The Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on A Stable Dose of GLP-1 Receptor Agonist PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy. |
ASTRAZENECA | 2025-05-13 |
| 64 | ERYTHRO Retrospective Medical Chart Review Study to Describe The Experience of SLE Patients Treated With Anifrolumab in The Early Access Programs PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The ERYTHRO study is a retrospective medical chart review study of patients in the AMANA and ATUc Early Access Programs (EAPs) across a number of countries, to assess anifrolumab usage and patient experience in treating SLE in a real-world setting. Since patient safety data are already collected and reported according to regulatory requirements through EAPs, this study will not collect safety data. |
ASTRAZENECA | 2025-05-13 |
| 65 | A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating The Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2). |
KAVEH AZIZI; | 2025-05-13 |
| 66 | Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up. |
ASTRAZENECA | 2025-05-13 |
| 67 | An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate The Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease. |
ASTRAZENECA | 2025-05-09 |
| 68 | A Translational Study in Patients With COPD and Early COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on early COPD, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants initially for 1-year period. The follow-up period may extend up to 3 years depending upon emerging data and feasibility assessment by the sponsor. |
ASTRAZENECA | 2025-05-09 |
| 69 | A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator’s choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2. |
ASTRAZENECA | 2025-05-09 |
| 70 | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer Who Are CtDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature. |
DAVID JONES; | 2025-05-09 |
| 71 | Osimertinib With Chemotherapy As First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-Small Cell Lung Cancer (NSCLC): A Multicentre, Observational Study (FOREFRONT) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: To estimate parameters related to clinical outcomes in a real-world seeting, including investigator reported PFS and OS. |
BAOHUI HAN; | 2025-05-09 |
| 72 | A Multi-arm, Open-label Phase I/IIa Study to Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. |
ASTRAZENECA | 2025-05-09 |
| 73 | An Ambispective, Non-interventional, Multiple Cohort Study to Assess The Management of Osimertinib Treatment in Patients With EGFRm Non-small Cell Lung Cancer Under Real-world Conditions in Spain PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Lung cancer (LC) is the tumor responsible for the highest mortality worldwide. Lung adenocarcinoma is the major subtype of lung cancer and represents the deadliest human cancer, affecting current-, ex-, and even non-smokers. Osimertinib is indicated as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations in the EGFR, for the treatment of adult patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC, and for the adjuvant treatment of adult patients with NSCLC stages IB-IIIA after complete resection of the tumor that has activating mutations of the EGFR. The FLAURA trial showed that treatment with osimertinib significantly prolongs PFS and improves overall survival (OS) compared to standard EGFR tyrosine kinase inhibitors. The results of the ADAURA study showed a reduction in the risk of recurrence or death by 83% in stages II to IIIA, and in 80% in stages IB-IIIA. Additionally, osimertinib demonstrated a highly statistically significant improvement in DFS and HRQoL was maintained. The FLAURA2 trial showed that first-line treatment with osimertinib-chemotherapy led to significantly longer progression-free survival than osimertinib monotherapy among patients with EGFR mutated (EGFRm) advanced NSCLC. To date, there are real-world data on osimertinib use in pretreated … |
ASTRAZENECA | 2025-05-09 |
| 74 | A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve. |
ASTRAZENECA | 2025-05-09 |
| 75 | AZAHAR Study. Observational Retrospective Study To Describe Characteristics And Clinical Outcomes of Patients With Systemic Lupus Erythematosus Initiating Saphnelo (Anifrolumab) in A Real-World Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: AZAHAR is an observational retrospective and longitudinal study with adults patients with SLE who initiated treatment with anifrolumab from June 1, 2023 to May 31, 2024. The overall objective is to describe the characteristics and clinical outcomes of patients with SLE that initiated anifrolumab during its first year of commercialization in Spain. |
JOSEFINA CORTÉS-HERNÁNDEZ; | 2025-05-09 |
| 76 | Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients Multicountry, Multicenter, Observational, Prospective, Primary Data, Real-world Settings PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, and Qatar), Latin America (Brazil, Argentina, and Colombia), and India. It is anticipated that the data generated will provide practical, patient-focused real-world evidence and enhance communications between patients and physicians in an objective and structured manner to ensure better disease control in patients under benralizumab treatment. |
ASTRAZENECA | 2025-05-09 |
| 77 | A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess The Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants |
ASTRAZENECA | 2025-05-09 |
| 78 | Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of study is to assess the safety, tolerability, and pharmacokinetic (PK) of benralizumab. |
ASTRAZENECA | 2025-05-09 |
| 79 | OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on The Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented. |
ASTRAZENECA | 2025-05-08 |
| 80 | A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults With Moderate to Severe Uncontrolled Asthma PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma. |
ASTRAZENECA | 2025-05-08 |
| 81 | A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess The Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT 1) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel |
PASI JÄNNE; | 2025-05-08 |
| 82 | A Phase II Study Assessing The Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib |
LECIA V SEQUIST; | 2025-05-08 |
| 83 | A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for The First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC. |
ASTRAZENECA | 2025-05-08 |
| 84 | A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma). |
TONI CHOUEIRI; | 2025-05-08 |
| 85 | Multicentre, Single Arm, Non-interventional, Observational, Prospective Study to Assess Demographic Characteristics, Burden of Disease and Short-term Patient Reported Outcomes on Symptom Relief in Severe Asthma Patients Aged Older Than 12 Qualifying for Treatment With Tezepelumab in Russia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab treatment initiation in participants with severe asthma in Russia. |
ASTRAZENECA | 2025-05-08 |
| 86 | A Phase II, Open-label, Single-arm Study of Osimertinib As Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-small Cell Lung Cancer (NEOLA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R). |
ASTRAZENECA | 2025-05-08 |
| 87 | Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil Related Papers Related Patents Related Grants Related Experts Highlight: A national, multicenter, retrospective, observational study (Real-World Evidence-RWE) aimed to assess the efficacy of Trastuzumab-deruxtecan (T-DXd) in patients with triple-negative (RE\<10%) metastatic HER2-Low breast cancer. |
ITALO FERNANDES; | 2025-05-08 |
| 88 | A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids. |
ASTRAZENECA | 2025-05-07 |
| 89 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy As Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator’s choice of chemotherapy in participants with BTC after surgical resection with curative intent. |
ASTRAZENECA | 2025-05-07 |
| 90 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for The First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1. |
ASTRAZENECA | 2025-05-07 |
| 91 | A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF). |
ASTRAZENECA | 2025-05-07 |
| 92 | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess The Equivalence of Budesonide and Albuterol (BDA) Delivered By MDI HFO Compared With BDA Delivered By MDI HFA in Participants With Asthma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma. |
ASTRAZENECA | 2025-05-07 |
| 93 | A Modular Phase I/II, Open-label, Multicentre Study to Evaluate The Safety, Tolerability, and Efficacy of AZD3470, A PRMT5 Inhibitor, As Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies. |
ASTRAZENECA | 2025-05-07 |
| 94 | A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant DdMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting. |
ASTRAZENECA | 2025-05-07 |
| 95 | PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, A MTA Cooperative PRMT5 Inhibitor, As Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumors That Are MTAP Deficient PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents. |
ASTRAZENECA | 2025-05-07 |
| 96 | A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate The Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma. Study details include: * The study duration for each participant will be approximately 10 weeks. * The duration of IMP administration will be approximately 4 weeks. |
ASTRAZENECA | 2025-05-07 |
| 97 | A Phase IIIB Study to Evaluate The Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed By Durvalumab With Olaparib As First-line Treatment in Patients With Newly Diagnosed PMMR Advanced or Recurrent Endometrial Cancer in Spain PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC as the primary endpoint. The study will include approximately 85 patients distributed in approximately 20 sites in Spain. The planned duration of patient recruitment is approximately 12 months. Each patient will be followed up from screening for 36 months, until end of study period, death, withdrawal from study or loss to follow-up; whichever occurs first. Enrolment will be opened to all eligible patients treated with durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC. In addition, adequate tumour tissue before study entry, stool and blood sample collected will be required for central analysis to monitor the status of relevant biomarkers. |
ASTRAZENECA | 2025-05-07 |
| 98 | Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting. |
ASTRAZENECA | 2025-05-06 |
| 99 | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed By THP Compared to DdAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer. |
ASTRAZENECA | 2025-05-06 |
| 100 | Post-Authorisation Safety Study of Paediatric Patients Initiating Selumetinib: A Multiple-Country Prospective Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant genetic disorder that is caused by germline mutations in the NF1 tumour suppressor gene, which encodes the tumour suppressor protein neurofibromin 1. Plexiform neurofibromas (PN) are histologically benign nerve sheath tumours, which typically grow along large nerves and plexi. On 5 March 2020, a centralised Marketing Authorisation Application was submitted to the European Medicines Agency (EMA), Marketing Authorisation in EU was granted on 17 Jun 2021. As part of the approval process, a Risk Management Plan (RMP) was developed and submitted to the EMA to summarise the safety concerns emerging from the clinical development program. The RMP included additional pharmacovigilance plans for a noninterventional Post-authorisation Safety Study (PASS) to further characterise the safety of selumetinib in paediatric patients with NF1-related PN in routine clinical practice. The planned non-interventional PASS will address gaps in knowledge identified by the RMP, including the important identified risk and some of the potential risks and missing information on long-term developmental toxicity in children, by characterising the safety profile associated with selumetinib use among paediatric patients (age d 8 to \< 18 years old) with a diagnosis of NF1 with symptomatic, inoperable PN. This study is a ... |
ASTRAZENECA | 2025-05-06 |
| 101 | REBECCA Real-world Early BrEast CanCer MAnagement REBECCA. A French National Multicentric Real-world Study of Early Breast Cancer Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician’s discretion. |
ASTRAZENECA | 2025-05-06 |
| 102 | An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children \<18 years of age. Approximately 140 participants will enter CP at approximately 46 sites in locations including but not limited to Europe and North America for this study. Treatment will include 3 phases: the CP, MP, and LTMP. Enrolment will start in 2 cohorts, ages 6 to \< 12 years and 12 to \< 18 years. After review of accumulated data, the independent Data Monitoring Committee (iDMC) will recommend whether to open enrolment in the ages 2 to \< 6 years cohort and later in the ages 0 to \< 2 years cohort. All eligible participants with hyperkalaemia will enter an open-label Correction Phase (CP) receiving a fixed dose of SZC three times daily (TID) for up to 3 days until normokalaemia is achieved. Within each age cohorts 2 to \< 18 years, initial participants will be allocated to the dose level (DL) based on body weight equivalent to an adult 5 ... |
ASTRAZENECA | 2025-05-06 |
| 103 | A Phase 1b/2 Study of AZD0120, A Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus. |
ASTRAZENECA | 2025-05-06 |
| 104 | Non-interventional Cohort Study of Patients Previously Untreated or First-generation BTKi Intolerant With Chronic Lymphocytic Leukemia Describing The First-line Use of Acalabrutinib and Its Real-world Outcomes in Spain: The PICAROS Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter non-interventional study (NIS) on patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit in Spain |
ASTRAZENECA | 2025-05-06 |
| 105 | A Phase I, Open-Label, Multi-center Study to Assess The Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being conducted to determine if a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated. The study will also investigate how AZD6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. Initial and periodic assessments will establish patient response to the combination therapies |
PATRICIA LORUSSO; | 2025-05-06 |
| 106 | A Phase I, Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of AZD6912 administered subcutaneously (SC) in healthy participants. |
ASTRAZENECA | 2025-05-06 |
| 107 | A Phase I, Open-Label, Multi-centre Study to Assess The Safety, Tolerability and Pharmacokinetics of A Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies. |
ASTRAZENECA | 2025-05-06 |
| 108 | A Multicentre Single Arm Observational Prospective Study to Assess Demographic Characteristics Burden of Disease PRO’s in Uncontrolled, Severe Eosinophilic Asthma Patients Aged 18y or Older and Qualifying for Treatment With Benralizumab in BE PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess health and quality of life outcomes in patients treated with benralizumab, within a Belgian Real-World setting. To prove the clinical value of benralizumab in a Real-World setting, the study will document the effect of benralizumab within a time frame of 112 weeks after initiation of treatment. |
DUPONT LIEVE; | 2025-05-06 |
| 109 | A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for The First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1). |
ASTRAZENECA | 2025-05-02 |
| 110 | A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity |
MELANIE DAVIES; | 2025-05-02 |
| 111 | A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, An Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sabestomig (AZD7789) in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL). |
ASTRAZENECA | 2025-05-02 |
| 112 | A Randomized, Double-blind, Multicenter, Parallel-group, Phase IIIb 52 Week Study Evaluating The Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year. |
ASTRAZENECA | 2025-05-01 |
| 113 | BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate The Efficacy and Safety of Benralizumab 30 Mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting Β2-Agonist PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA. |
SANDEEP BANSAL; | 2025-05-01 |
| 114 | A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 As Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2. |
ASTRAZENECA | 2025-05-01 |
| 115 | TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs |
ASTRAZENECA | 2025-05-01 |
| 116 | FASENRA® Subcutaneous Injection 30 Mg / 10mg Syringe Protocol of Specific Drug Use Result Study for Pediatric Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the investigation is to confirm the followings under the post-marketing actual use of Fasenra® Subcutaneous Injection 30 mg / 10mg Syringe (hereinafter referred to as Fasenra). 1. Development of unexpected related AEs\* 2. To grasp development of related AEs\* in the real-world post-marketing setting. 3. Effectiveness (pulmonary function and asthma control) \* AEs investigator or MAH considers that there is a reasonable possibility that the experience may have been caused by the drug |
ASTRAZENECA | 2025-05-01 |
| 117 | Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess The Effects and Safety of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment Related Papers Related Patents Related Grants Related Experts Highlight: A study to investigate the effects and safety of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment. |
ASTRAZENECA | 2025-05-01 |
| 118 | FASENRA Subcutaneous Injection 30 Mg Syringe Specific Clinical Experience Investigation for Long-term Use PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe. |
ASTRAZENECA | 2025-04-30 |
| 119 | Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM. |
GUANG WANG; | 2025-04-30 |
| 120 | DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC. |
ASTRAZENECA | 2025-04-30 |
| 121 | A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS). |
ASTRAZENECA | 2025-04-30 |
| 122 | Study on Clinical Use of Evusheld (AZD7442) in The Real-world Setting – A Multi-Centre, Single-arm, Observational Study to Determine The Utilisation and Clinical Outcomes of Evusheld in China PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Evusheld(AZD7442) is a combination of 2 human long-acting antibodies, which was selected for maximal potency and demonstrated synergistic neutralization of SARS-CoV-2 in vitro. PROVENT is a Phase III study in participants at an increased risk for inadequate response to COVID-19 vaccine, an increased risk of exposure to SARS-CoV-2 or both. The study met the primary endpoint of reduction in the incidence of symptomatic Coronavirus disease 2019 (COVID-19) with tixagevimab/cilgavimab (TIXA/CILGA) compared with placebo, risk reduction 76.7% (95% CI, 46.0-90.0), in 5172 patients who did not have a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Reverse transcription polymerase chain reaction (RT-PCR) positive COVID-19 infection at baseline. Although the PROVENT trial was invaluable in demonstrating AZD7442’s ability to prevent symptomatic infection, it was conducted in highly controlled environments using a rigorous protocol, which does not accurately reflect the patient experience in clinical practice. Furthermore, the sample size of Asian population in phase 3 clinical trials is small (110 subjects in AZD7442 group and 60 subjects in placebo group), and there is very limited clinical trial/real-world data in Chinese population is reported. Therefore, this current study aims to describe the utilisation and clinical outcomes of AZD7442 in Chinese population for pre-exposure prophylaxis. |
JIEMING QU; | 2025-04-30 |
| 123 | A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore The Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer |
KOMAL JHAVERI; | 2025-04-30 |
| 124 | A Prospective Observational Study to Evaluate Real-world Clinical Outcomes and Characteristics of Patients With MCRPC Treated With Olaparib + Abiraterone PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in. |
ASTRAZENECA | 2025-04-30 |
| 125 | A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate The Efficacy and Safety of Novel Immunomodulators As Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors. |
ASTRAZENECA | 2025-04-30 |
| 126 | An Open-label, Randomized, Multicenter, Phase 3 Study to Assess The Efficacy and Safety of Trastuzumab Deruxtecan As First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations |
ASTRAZENECA | 2025-04-30 |
| 127 | A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly And/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments. |
ASTRAZENECA | 2025-04-30 |
| 128 | A Phase I, Randomised, Investigator- and Participant-blinded, Placebo-Controlled, Study to Assess The Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Obesity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to evaluate the safety and tolerability, and pharmacodynamics (PD) of AZD4144 administered as repeated daily oral dosing. |
ASTRAZENECA | 2025-04-30 |
| 129 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator’s choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC. |
ASTRAZENECA | 2025-04-29 |
| 130 | A Phase III Randomized, Open-Label, Multicenter Study to Determine The Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC). Volga trial consists of two parts: Safety Run-In and Main Study. In total the study aims to enroll approximately 677 patients, who will receive triplet combination, duplet combination or currently approved SOC in the main trial. In the main part of the trial there is two out of three chances of being on a treatment arm and the treatment is assigned at random by a computer system. In this trial patients in the two treatment arms will receive either 3 cycles of neoadjuvant Durvalumab + Tremelimumab + Enfortumab Vedotin or Durvalumab + Enfortumab vedotin and after surgery both treatment arms will continue with adjuvant Durvalumab. |
ASTRAZENECA | 2025-04-29 |
| 131 | ASTER: Anifrolumab Study for Treatment Effectiveness in The Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Anifrolumab Study of Treatment Effectiveness in the Real World (ASTER) study will collect real world data to obtain a good understanding of the (sustained) clinical effect and patient quality of life outcomes among diagnosed SLE patients who initiate anifrolumab treatment. ASTER will generate critical real-world evidence on the benefits of adding anifrolumab to standard of care treatment for SLE in routine clinical practice, to inform physicians, payers and patients. |
ASTRAZENECA | 2025-04-29 |
| 132 | A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for The First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations. |
SURESH S. RAMALINGAM; | 2025-04-29 |
| 133 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate The Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) |
MEILAN HAN; | 2025-04-29 |
| 134 | A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate The Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) |
DAVE SINGH; | 2025-04-29 |
| 135 | A Randomised, Double-blind, Active-controlled 52-week Study With An Open-label Extension to Evaluate The Efficacy and Safety of Benralizumab Compared to Mepolizumab in The Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy. All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year). |
MICHAEL WECHSLER; | 2025-04-29 |
| 136 | Retention Rate of Acalabrutinib in A Non-interventional Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany. |
ASTRAZENECA | 2025-04-29 |
| 137 | Imjudo & Imfinzi Post-Marketing Surveillance PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated according to the approved indications in Korea. |
ASTRAZENECA | 2025-04-29 |
| 138 | IdentiFy AttRibutes Of UNcontrolled Severe AsThma Patients TrEateD With Tezepelumab: Italian Clinical Practice Study With The New BioloGic TargEting TSLP PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This observational study aims to collect data in clinical practice on the clinical profile of patients treated with Tezepelumab from Q1 2024 to Q1 2025 according to the approved and reimbursed indication in Italy |
ASTRAZENECA | 2025-04-29 |
| 139 | A Phase I, Randomized, Double-blind, Single-dose, Partial-replicate, 3-way Cross-over Study to Assess The Total Systemic Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered By BGF MDI HFO Compared With BGF MDI HFA PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study will evaluate bioequivalence, pharmacokinetics, safety, and tolerability of Budesonide, Glycopyrronium and Formoterol (BGF) metered dose inhaler (MDI) formulated with hydrofluoroolefin (HFO) \[Test\] and hydrofluoroalkane (HFA) \[Reference\] in healthy participants (male or female). |
ASTRAZENECA | 2025-04-29 |
| 140 | A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate The Efficacy and Safety of Anifrolumab in Adults With Chronic And/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory And/or Intolerant to Antimalarial Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE). |
ASTRAZENECA | 2025-04-29 |
| 141 | A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise The Pharmacokinetics and Pharmacodynamics of AZD4604 Administered Via The Turbuhaler® Device in Adults With Mild Asthma PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the multiple doses of AZD4604 via Turbuhaler device. |
ASTRAZENECA | 2025-04-29 |
| 142 | A Phase II, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate The Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With A History of COPD Exacerbations and Elevated Eosinophils (COMETA) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or placebo administrations in participants with symptomatic chronic obstructive pulmonary disease (COPD) with history of exacerbations and high blood eosinophil counts. Study details include the following: * The maximum duration of the screening/run-in period is 5 weeks. An additional unscheduled visit may be performed prior to randomization to repeat safety assessments as deemed necessary by the investigator. * Eligible patients will enter 12-week treatment (intervention) period with site visits and investigational product (IP) administration every 2 weeks. * Participants who complete a treatment period, and have not been prematurely discontinued from IP, will enter a 10-week post-intervention follow-up period. * The study duration will be 27 weeks at maximum for each participant. |
ASTRAZENECA | 2025-04-29 |
| 143 | A Phase I/II Open Label Study to Evaluate The Safety, Cellular Kinetics, and Efficacy of AZD0754, A Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants With Metastatic Prostate Cancer: APOLLO PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer. |
ASTRAZENECA | 2025-04-29 |
| 144 | An Open-label, Fixed Sequence Study in Healthy Participants to Assess The Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants. |
ASTRAZENECA | 2025-04-29 |
| 145 | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate The Use of Benralizumab As A Treatment Option for Patients With Bullous Pemphigoid (FJORD) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP). |
JANET A. FAIRLEY; | 2025-04-28 |
| 146 | An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing The Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on The Pharmacokinetics of AZD4144 in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The main aim of this study to compare the pharmacokinetics (PK) of two formulations of AZD4144 and assess the effect of food and omeprazole on PK of AZD4144 in healthy participants. |
ASTRAZENECA | 2025-04-28 |
| 147 | Descriptive Study of The Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, A Post Authorization Safety Study PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This is a real-world, observational, prospective cohort study in patients with severe asthma recruited into the International Severe Asthma Registry (ISAR) and the US severe asthma registry (CHRONICLE) and followed-up for occurrence of new malignancies. The primary objective is to measure the incidence of malignancy in the overall severe asthma population as well as its relevant subgroups, including patients receiving benralizumab, patients receiving non-benralizumab biologics, and patients not receiving biologics. The secondary objective is to describe the clinical characteristics of new malignancy cases that develop in severe asthma patients and relevant subgroups. |
ADRIAN P.J. RABE; | 2025-04-25 |
| 148 | Establishment of A FeNO Cutoff Value for Evaluating The Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: A Multicenter Prospective Clinical Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO. In this study, the response to ICS/LABA treatment is defined as reduction in cough VAS score from baseline of ≥30 mm after 8 weeks of ICS/LABA treatment. Subjects will be treated with Symbicort® 160/4.5 mcg, 1 puff, BID for 8 weeks with 4 study visits: Visit 1 (Day 0), Visit 2 (week 4) and Visit 3, end of study (week 8) and Visit 4, 4 weeks after treatment discontinuation, (week 12). Baseline data will be collected at Day-5 to Day0. This study will be conducted at around 40 study sites in China. Approximately 1000 patients (age ≥18 years old) with dry cough or nocturnal cough symptoms for at least 8 weeks and no other obvious cause for their cough will be enrolled into this study. |
KEFANG LAI; | 2025-04-25 |
| 149 | A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 As Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in 490 participants with advanced cancer that has recurred/progressed. |
ASTRAZENECA | 2025-04-25 |
| 150 | RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2022. |
ASTRAZENECA | 2025-04-25 |
| 151 | A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate The Efficacy and Safety of Acalabrutinib Versus Chlorambucil Plus Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia. |
LUGUI QIU; | 2025-04-25 |
| 152 | Specific Use-results Study of IMJUDO Intravenous Infusion 25 Mg, 300 Mg / IMFINZI Intravenous Infusion 120 Mg, 500 Mg All Patient Investigation in Patients With Unresectable Hepatocellular Carcinoma PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This investigation will be conducted to collect information of safety in patients with unresectable hepatocellular carcinoma (HCC) treated with the combination therapy of IMJUDO 25 mg, 300 mg and IMFINZI Intravenous Infusion 120 mg, 500 mg or with IMFINZI monotherapy under actual use in the post-marketing setting. |
ASTRAZENECA | 2025-04-25 |
| 153 | A Phase II, Open-label Study to Evaluate The Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors. |
ASTRAZENECA | 2025-04-25 |
| 154 | A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate The Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis |
ASTRAZENECA | 2025-04-25 |
| 155 | A Single-centre, Randomised, Double-blind, Placebo-controlled, Four-Way Crossover Phase I Thorough QTc Study to Investigate The Effect on QTcF of Single Doses of Baxdrostat Compared With Placebo, Using Open-label Moxifloxacin As A Positive Control, in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia’s formula (QTcF) compared to placebo using a concentration-QTcF analysis, and with moxifloxacin as positive control, in healthy participants. |
ASTRAZENECA | 2025-04-25 |
| 156 | An Ambispective Observational Multicenter Registry of Patients With Uncontrolled Asthma in The Population of The Russian Federation PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multi-centre, non-interventional, observational, ambispective registry. Planned study population consists of 10 000 adult patients with uncontrolled asthma receiving treatment according to standard of care (except biologics). Planned number of study site is 70 outpatient centers with experience of uncontrolled asthma treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled asthma in different regions in the most comprehensive way). |
ASTRAZENECA | 2025-04-24 |
| 157 | A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess The Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS) PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk. |
ASTRAZENECA | 2025-04-24 |
| 158 | A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate The Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO. |
ASTRAZENECA | 2025-04-24 |
| 159 | A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Chinese Atypical Hemolytic Uremic Syndrome Patients PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a China, non-interventional, observational study and will follow the Good Phar-macoepidemiology Practices guidelines. This study will enrol paediatric and adult patients diagnosed with aHUS who will be treated according to routine clinical practice defined by local institutional treatment guidelines/protocol. Those aHUS patients who will be treated with a supportive therapy, which does not contain eculizumab, will be monitored for up to 12 months since the ini-tial diagnosis. Patients initiated on eculizumab treatment anytime between aHUS diagno-sis until 12 months will be followed for additional 12 months, starting from the ecu initia-tion. Patient disposition, characteristics, outcomes and safety will be described for all pa-tients enrolled into this study |
ASTRAZENECA | 2025-04-24 |
| 160 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT. |
ASTRAZENECA | 2025-04-24 |
| 161 | A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. |
MARJORIE G ZAUDERER; | 2025-04-24 |
| 162 | A Phase II Study to Evaluate The Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). |
ASTRAZENECA | 2025-04-24 |
| 163 | A Phase I/IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate The Safety and Pharmacokinetics of AZD7760 in Healthy Participants and in Patients With End-stage Kidney Disease Receiving Hemodialysis Through A Central Venous Catheter PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa). |
ASTRAZENECA | 2025-04-24 |
| 164 | Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication. |
ASTRAZENECA | 2025-04-24 |
| 165 | A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275. |
ASTRAZENECA | 2025-04-24 |
| 166 | A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate The Efficacy and Safety of Anifrolumab Administered As Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment. |
ASTRAZENECA | 2025-04-24 |
| 167 | Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This survey will be conducted to investigate the status of occurrence of the safety specifications set for Safety specification in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions. |
ASTRAZENECA | 2025-04-24 |
| 168 | General Use-Results Study of Calquence Capsules 100 Mg in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use |
ASTRAZENECA | 2025-04-24 |
| 169 | A Phase I, Open Label, Non-Randomised Study to Assess The Effect of Rifampicin on The Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer. |
MICHAEL SAWYER; | 2025-04-24 |
| 170 | A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice daily \[bd\]) compared to investigator’s choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of \< 50%. Randomisation will be stratified by LVEF \> 40% vs ≤ 40% to stratify for moderate and severe cardiac impairment, which for this study are defined as follows: Severe cardiac impairment: in those with LVEF ≤ 40% Moderate cardiac impairment: in those with LVEF \> 40% to \< 50%. The study is planned to take place in approximately 20 centres globally. The study will be conducted in centres that have established close collaboration between the Haematology and Cardiology divisions, preferably with a cardio-oncologist on the team. An IDMC will be responsible for making recommendations for study continuation. |
ASTRAZENECA | 2025-04-24 |
| 171 | A Phase II Single-arm Multi-centre Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum Based, Concurrent Chemoradiation Therapy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT). |
ASTRAZENECA | 2025-04-24 |
| 172 | A Phase I, Randomized, Double-blind, Placebo-controlled, Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AZD1163 Administered As Single and Multiple Ascending Doses in Healthy Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A study to demonstrate the safety and tolerability of AZD1163 when administered intravenously and subcutaneously in healthy participants. |
ASTRAZENECA | 2025-04-24 |
| 173 | An Observational Multi Center Study to Evaluate Real World Treatment Outcomes of Durvalumab Based Regimens in Hepatobiliary Cancers PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data collection. The primary objective of this study is to evaluate the effectiveness of durvalumab-based regimens in real-world settings as measured by real-world overall survival. Other endpoints include demographics, clinical characteristics, clinically significant events of interest, treatment patterns, concomitant medications, and other real-world clinical endpoints (such as duration of treatment, progression-free survival, time to treatment progression, time to next treatment, recurrence-free survival, and time to treatment recurrence). |
ASTRAZENECA | 2025-04-23 |
| 174 | A Phase IB, Open-Label, Multi-Center Study to Determine The Efficacy and Safety of Durvalumab And/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC) |
SANDIP PATEL; | 2025-04-23 |
| 175 | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate The Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of The PNPLA3 Rs738409 148M Risk Allele PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele |
ASTRAZENECA | 2025-04-23 |
| 176 | A Phase I/IIa, Open-label, Multi-centre Study to Assess The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring A KRASG12D Mutation (ALAFOSS-01) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants with tumours harbouring a KRASG12D mutation. |
ASTRAZENECA | 2025-04-23 |
| 177 | ROSY-D: Roll Over StudY for Patients Who Have Completed A Previous Oncology Study With Durvalumab and Are Judged By The Investigator to Clinically Benefit From Continued Treatment PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. |
ASTRAZENECA | 2025-04-23 |
| 178 | A Study to Assess The Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily Via Inhalation, for 2 Weeks, in Adults With Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomised, placebo-controlled, double-blinded, sponsor-unblinded study to assess the safety, pharmacokinetic (PK), and pharmacodynamic (PD) effect of AZD8630 in adult participants with asthma on medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). |
ASTRAZENECA | 2025-04-23 |
| 179 | A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy As First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase IIIb, open-label, single arm, multicentre study to assess the safety and efficacy of durvalumab in combination with investigator’s choice of 3 different gemcitabine-based chemotherapy regimens in participants with aBTC with a WHO/ECOG PS of 0 to 2 at enrolment. |
ASTRAZENECA | 2025-04-22 |
| 180 | A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess The Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations And/or Co-mutations in STK11, KEAP1, or KRAS (TRITON) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS. |
ASTRAZENECA | 2025-04-22 |
| 181 | Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure And/or Chronic Kidney Diseases PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes, Hypertension, Heart failure and/or Chronic kidney diseases |
ASTRAZENECA | 2025-04-18 |
| 182 | A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on The Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected. |
ASTRAZENECA | 2025-04-18 |
| 183 | A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population |
ASTRAZENECA | 2025-04-18 |
| 184 | Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup. |
ASTRAZENECA | 2025-04-18 |
| 185 | A Real-world, Multicenter, 52-week Prospective Cohort Study to Capture The Reasons for Switch to Triple Combination Therapy and to Assess The Clinical and Patient Reported Outcomes in Adults With Moderate to Severe COPD Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Chronic obstructive pulmonary disease (COPD) is a debilitating and progressive respiratory condition characterized by irreversible airflow limitation. The overall 5-year survival for COPD patients is 56-92%, depending on disease severity. Considering the recent introduction of the Budesonide, Glycopyrronium bromide and Formoterol fumarate Metered-Dose Inhaler (BGF MDI) in COPD therapeutic arsenal as well as the increasingly important role of real-world (RW) data in health care decisions, as it bridges gaps not addressed by randomized clinical trials, there is a need for RW evidence studies that can serve as inputs for Health Technology Assessment (HTA) submissions. In view of this need, this study is designed to generate RW evidence on the clinical and patient-reported outcomes of treatment with BGF MDI over a 52-week treatment period in routine care settings in Greece as well as to shed light on the reasons for switching from dual to triple therapy with BGF MDI, aiming at further characterizing the multifactorial aspects of inadequate COPD management that lead physicians to step-up treatment. The study is mainly descriptive in nature and is not planned to reject or affirm any formal statistical hypothesis. This is a single-country, non-interventional, multicenter, 52-week prospective cohort study, mainly based on primary data collection, … |
ASTRAZENECA | 2025-04-18 |
| 186 | A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 As Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents. |
CHARU AGGARWAL; | 2025-04-18 |
| 187 | A Multicentre, Single-Arm, Phase 3b Study to Assess Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab (ESSENCE) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W). |
TANYA M LAIDLAW; | 2025-04-18 |
| 188 | A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants With Overweight or Obesity PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity |
ASTRAZENECA | 2025-04-18 |
| 189 | A Phase 2, Multicenter, Open-label Study to Evaluate The Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for The Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ovarian cancer, and E) HER2 IHC 2+ or 1+ cervical cancer. Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favorable risk benefit profile in selected HER2-expressing solid tumors. |
ASTRAZENECA | 2025-04-18 |
| 190 | An Observational, Prospective, Multicenter Study to Evaluate The Biologic Use and Outcomes in Chinese Asthma Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician. |
YUBIAO GUO; | 2025-04-18 |
| 191 | A Phase I, Multicentre Study to Assess The Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy |
PATRICK WEN; | 2025-04-18 |
| 192 | Open-Label, Uncontrolled, Single Dose Study to Evaluate The Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 Weeks Gestational Age to < 18 Years PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD7442 administered intramuscularly (IM) or intravenously (IV) in pediatric participants aged ≥ 29 weeks GA to \< 18 years. |
ASTRAZENECA | 2025-04-18 |
| 193 | An Open-label, Randomised, Parallel-group, Fixed-sequence Study to Assess The Effect of Oral Ticagrelor on The Pharmacokinetics of Oral Rosuvastatin in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to measure the effect of ticagrelor on the pharmacokinetics (PK) of rosuvastatin in healthy participants. |
ASTRAZENECA | 2025-04-18 |
| 194 | A Multicenter, Prospective Cohort Study in Patients With Myasthenia Gravis in China PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027. |
FUDONG SHI; | 2025-04-17 |
| 195 | A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine The Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for The First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer |
ASTRAZENECA | 2025-04-17 |
| 196 | A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab As Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy. |
YILONG WU; | 2025-04-17 |
| 197 | A Phase Ib Multicenter, Open-label Study to Evaluate The Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint. |
ASTRAZENECA | 2025-04-17 |
| 198 | A Phase 1/2a, Open-label, Multicenter Study to Evaluate The Safety, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous Durvalumab in Patients With Non-Small Cell and Small Cell Lung Cancer – SCope-D1 PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study has 2 parts: dose finding and dose confirmatory. In Part 1, the dose finding phase of the study, there will be 3 or more dosing levels to find out what dose of durvalumab administered as an infusion under the skin acts similarly to durvalumab administered into a vein. 24 participants with Non-Small Cell Lung Cancer will be enrolled for a 12 month treatment period and 3 months follow up In Part 2, the dose confirmation phase of the study, participants will receive the dose of durvalumab identified in Part 1 of the study. The goal of Part 2 will be to learn more about the way that the body processes durvalumab when administered as an infusion under the skin. Approximately 90 participants with Non-Small Cell Lung Cancer will be enrolled; additionally, up to 10 participants with Small Cell Lung Cancer (who will receive concurrent chemotherapy) will be enrolled for a 12 treatment period and a 3 month follow-up period. AstraZeneca has decided to stop further enrollment and the study was terminated when all patients in Part 1 (Phase I) completed their last study visit. No safety issues or clinical concerns however, have been identified for this study. Part … |
ASTRAZENECA | 2025-04-17 |
| 199 | Forxiga Tablets 5mg, 10mgGeneral Drug Use-Results Study N in Chronic Kidney Disease (CKD) Patients PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: To capture safety when Forxige is administrated to CKD patients in the real world setting |
ASTRAZENECA | 2025-04-16 |
| 200 | Real World Outcomes and Treatment Patterns in Brazilian Patients With Hormone Receptor Positive / HER2-negative Unresectable or Metastatic Breast Cancer PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a descriptive, retrospective, observational study to generate Real-World Evidence (RWE). This study will evaluate the treatment patterns and outcomes with metastatic or unresectable hormone receptor-positive breast cancer in Brazil. No hypotheses will be tested. |
ASTRAZENECA | 2025-04-16 |